eral Hospital, published guidelines, a review of the medical literature, and experience gained from answering calls to our National HIV Telephone Consultation Service (\VarmIine). Because HIV disease management changes rapidly, clinicians are advised to refer to the excellent federal guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents 3 and for prevention of opportunistic infections. 4 The guidelines are updated frequently on the Internet (fable 2), and these and other federal guidelines are available at http://www.hivatis.org.
Antiretroviral Therapy
The key determinants of effective antiretroviral therapy are the selection of a potent regimen and the patient's ability to adhere to the medication regimen. Antiretroviral regimens can be difficult to take. Multiple daily doses, a large pill burden, drug side effects, and the necessity to administer some medicines either with or without food can make adherence difficult even for the most well-intentioned and motivated patient. The commitment must be to take these drugs daily without interruption on a lifelong basis. The primary care clinician and the patient must acknowledge these inherent difficulties and develop realistic expectations before antiretroviral treatment begins. Adherence should be reevaluated regularly during treatment because inadequate adherence can rapidly lead to virologic resistance to the entire class of drugs as well as the specific drugs used. Although there might be some temporary improvement in laboratory values or even in some clinical manifestations of HIV disease when less potent treatment regimens are used or regimen adherence is poor, such suboptimal approaches appear to be poor long-term strategies. It is better to withhold antiretroviral therapy if careful adherence to potent treatment regimens cannot be maintained. Embarking on antiretroviral therapy is a major decision. Patients need to understand that the first regimen is usually the simplest and most effective regimen. Subsequent regimens after failed therapy (salvage regimens) are often more difficult to take, antagonists, and drugs (eg, ketoconazole, itraconazole, indinavir, delavirdine, ritonavir, tetracyclines, quinolone antibiotics) whose absorption is impaired by buffered products 
Drug interactions
Clarithromycin increases serum levels of rifabutin and can lead to rifabutin toxicity, including severe anterior uveitis. Clarithromycin and azithromycin increase levels of carbamazepine, theophylline, and digoxin Nausea (can be reduced by administering 150 mg PO bid). Rash. Uveitis with dosages greater than 300 mg PO qd and in patients receiving concomitant c1arithromycin, fluconawle, or PI therapy.
Red-orange discoloration of body fluids.
Rare neutropenia, thrombocytopenia, anemia; flu-like syndrome; elevated bilirubin and alkaline phosphatase levels, hepatitis
Multiple interactions with PIs. See individual PIs, above. Rifabutin increases metabolism of methadone, zidovudine, and c1arithromycin; higher dosage of these drugs might be required. Oarithromycin increases rifabutin blood levels and can lead to rifabutin toxicity Optic neuritis (if> 25 mglkg/d); hypenwncemia;nausea,vomiting Nausea, vomiting, diarrhea. Reversible pink to brown-black discoloration of skin, eyes, body secretions; rash. Hyperglycemia. Treatment of AIDS and liN-Related Conditions 283 Consider discontinuing PCP primary prophylaxis in persons whose CD4 + cell count increases to >200/jLL for more than 3-6 months in response to antiretroviral therapy TMP-SMX considered most effective for prophylaxis. TMP-SMX provides additional prophylaxis against toxoplasmosis and common bacterial infections Probably less effective than TMP-SMX; might be less toxic. Check glucose-6 phosphate dehydrogenase (G6PD) betore starting dapsone. Lower dosages (eg, 100 mg PO 2 times a week) might be effective Take with tood to increase drug absorption. Patients with enteropathy might not absorb a sufficient amount of atovaquone for adequate treatment. Better tolerated than dapsone; efficacy similar Prednisone PO or 21 days methylprednisolone (SoluMedrol) IV, each given as follows: 40 mg bid for 5 days followed by 40 mg qd for 5 days, followed by 20 mg qd for 11 days (can be tapered to 0 mg for last 11 days also) Mointenmzct (secondary Indefinitely prophylaxis) with agents used for primary prophylaxis (above) 
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Goals of Therapy
The principal goal of therapy is to prevent or reverse the progression of clinical illness. Effective antiretroviral therapy is indicated by improvement in the clinical signs and symptoms of lllV disease (such as weight gain, reduction of oral candidiasis, and improved sense of well-being), a rising CD4 + cell count, and decreasing viral load. Some reduction in viral load should be apparent within 4 to 6 weeks of therapy.
Ideally, the viral load will decrease to undetectable levels (less than 50 copies/mL by the branched DNA [bDNA] assay) within 4 to 6 months. Patients who obtain substantial decreases in viral loads, but not to undetectable levels, can still obtain clinical benefit from antiretroviral therapy. The goal of therapy, however, should be to achieve viral suppression to undetectable levels or levels as close to undetect'able as possible. Effective therapy is usually accompanied by a CD4+ cell count increase of 100-200/J.LL or more within 2 to 4 months.
Initiating Antiretroviral Therapy
All patients with symptomatic lllV disease, low CD4 + counts, or high lllV RNA (viral load) levels are candidates for antiretroviral therapy. Laboratory markers should be repeated before deciding to treat. Current Department of Health and Human Services recommendations for initiating antiretroviral therapr are a CD4+ cell count of fewer than 500/j.LL or HIV RNA levels of more than 10,000 copieS/mL (bDNA assay) or 20,000 copieS/mL (RT-PCR assay). The International AIDS Society -USA s recommends an absolute CD4 + cell threshold of 350/j.LL and viral load of more than 5000 copieslmL for initiating therapy, with the CD4 + cell count range of 350-500/J.LL being optional. We generally favor either a CD4+ cell countof350/J.LL or a (bDNAassay) HIV RNA threshold of 10,000 copies/mL for encouraging antiretroviral therapy. All experts agree that the ideal time to begin therapy should be individualized. For example, persons who wish to have antiretroviral therapy initiated at CD4 + cell count levels greater than 350/j.LL or with detectable viral loads at any level should be offered antiretroviral therapy if they are committed and able to adhere to the medication regimens. Conversely, the patient who cannot take the medications consistently should not risk the development of resistance, regardless of laboratory markers. of high viral load, this outcome is not predictable, so alternative antiretroviral regimens should be sought. Antiretroviral therapy can fail because of poor adherence, acquired drug resistance, poor drug absorption, drug-drug interactions, or lack of drug potency. These factors need to be assessed to determine the proper intervention. Regardless of the cause of antiretroviral therapy failure, resistance testing can provide valuable information in selecting antiretroviral regimens.
Recommended Antiretroviral Drug Combinations
Resistance Testing
Resistance testing is an important adjunct in making decisions about changing therapies. The test should be obtained while the patient is taking the failing regimen. Some words of caution are in order: genotypic resistance tests are not well standardized, all laboratories do not provide equally accurate information, the reports can be difficult to interpret, the correlation between resistance testing results and clinical effectiveness (or lack of effectiveness) of drugs has not been established adequately, and often only the predominant viral population (not minor strains) is tested. Nevertheless, resistance testing can be most helpful in selecting a new drug regimen by determining drugs to which the patient's predominant virus might be resistant. Phenotypic resistance testing is presumably more accurate than genotypic testing, but it is more expensive, and correlation with clinical outcomes has not yet been established. Current resistance testing methods are expensive ($300 to $1,200) and are variably covered by third party payers. Additional resistance testing and reporting methods are being developed.
Cbanging Antiretroviral Therapy
All drugs of a failing antiretroviral regimen are usually discontinued. Before doing so, however, it is prudent to obtain resistance tests (while the patient is still receiving that failing regimen) to guide decisions about alternative drug regimens. Multiple drug resistance is often encountered, so antiretroviral regimen selection can be challenging. The new regimen requires at least two (and usually three to five) new agents from different antiretroviral classes, and sometimes drugs from all three classes. Dual protease inhibitor therapy should be considered strongly in these cases. Clinical resistance to stavudine, didanosine, or both is uncommon; these NRTIs can often be included in a salvage regimen. Consultation with an expert AIDS clinician is often required.
The strategy of discontinuing all antiretroviral drugs (scheduled treatment interruptions) is under investigation. There have been several reports describing reversion of the predominant virus to a sensitive (wild type) virus after weeks to months off antiretroviral treatment. This approach is not recommended unless all other options have failed.
Complications of Antiretroviral Therapy
Table llists the major complications of drugs used in HN disease. As patients survive longer, additional complications have been noted. Some complications are class related. The NRTI drug class appears to be associated with lipodystrophy, hepatomegaly, glucose intolerance, and lactic acidosis. Many NRTI side effects have been attributed to NRTI-induced mitochondrial toxicity. For patients with unexplained systemic illness, the presence of metabolic acidosis with anion gap should prompt an evaluation of the serum lactate level to confirm the diagnosis oflactic acidosis. This condition can be fatal and requires discontinuation of all NRTI drugs. An alternative antiretroviral regimen should be developed, because rechallenge with NRTI drugs is contraindicated. Lipodystrophy, hyperlipidemia, and hyperglycemia have also been associated with the protease inhibitor class of drugs. The clinical importance of the various lipid abnormalities in HN disease and AIDS has not been fully assessed; long-term development of coronary artery disease is of concern.
Paradoxical responses to effective antiretroviral therapy can occur. As the immune system improves, inflammatory responses to latent opportunistic infections, including uveitis in patients with cytomegalovirus (CMV) disease and acute adenitis in patients with mycobacterial diseases, can occur. These clinical flares should not be considered to be adverse clinical deteriorations; antiretroviral therapy should continue.
Opportunistic Infections
Opportunistic infections have decreased markedly since the introduction of potent antiretroviral therapy. Nevertheless, primary prophylaxis against Pneumocystis carinii pneumonia (PCP) and Mycobacterium avium complex (MAC) disease remains important.
Prophylaxis against PCP is essential for all patients with symptomatic HN disease, including those with CD4+ cell counts of less than 200/~L. Prophylaxis against MAC is recommended after the CD4 + cell count decreases to fewer than 50/~L. Prophylaxis against PCP and MAC disease can be continued as long as drug toxicities or problematic drug-drug interactions do not occur.
An alternative and equivalent strategy to continued prophylaxis is discontinuing primary opportunistic infection prophylaxis if substantial immune reconstitution has occurred in response to antiretroviral therapy.6 Prophylaxis against PCP can be discontinued when CD4+ cell counts have been more than 200/~L for 3 to 6 months. Similarly, MAC prophylaxis can be discontinued if the CD4 + cell count has been more than 100/~L for 3 to 6 months. 7 If substantial viral loads (more than 10,000 copies/mL by bDNA assay) are present, this strategy might not be as effective.
Although clinical studies generally have used a 6-month time frame to assess the adequacy of this strategy, discontinuing prophylaxis after 3 months appears safe as long as careful observation is possible. The strategy used for PCP prophylaxis will be satisfactory for toxoplasmosis prophylaxis in most instances. Discontinuing secondary PCP prophylaxis (ie, maintenance therapy after PCP has occurred) after 3 to 6 months of immune recovery of a CD4 + cell count to 200 /~L appeared safe in preliminary results from some studies and is a reasonable approach, especially if trimethoprim-sulfamethoxawle toxicity occurs. Discontinuing maintenance therapy (secondary prophylaxis) for cytomegalovirus appears safe in patients who have maintained CD4 + cell counts of more than lOO-150/~L for more than 3 to 6 months in response to antiretroviral therapy. Because maintenance therapy against cytomegalovirus can be associated with drug toxicity, this strategy is preferred. Tuberculosis coinfection with HN requires special management concerns. 8 ,9 Tuberculosis prophylaxis is essential for persons with a positive tuberculin skin test (greater than 5 mm in HN-infected persons), for persons with a previously positive tuberculin skin test without previous chemoprophylaxis, and for those who have had recent contact with active tuberculosis. Prophylaxis regimens are isoniazid for 9 months or isoniazid plus pyrazinamide or rifampin (or rifabutin) for 2 months. Treatment of active tuberculosis in HN-infected persons and prophylaxis against possible multi drug-resistant tuberculosis usually require consultation with tuberculosis experts.
The Table   Table 1 gives our recommendations for treating specific diseases and the major symptoms of HN disease and AIDS. The recommendations are principally in
Treannent of AIDS and lIN-Related Conditions 297 order of efficacy. \Vhere more than one drug is effective for a specific condition, recommendations are usually in an order that favors the least expensive choice among equally effective options. The most common and clinically important adverse effects and drug interactions are listed.
Sources of Infonnation
The most helpful and up-to-date sources of information can now be found on the Internet. Especially useful Web sites are listed in Table 2 . A selected bibliography highlights some additional articles of clinical interest. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Our National HIV Telephone Consultation Service (Warmline) in the University of California, San Francisco, Department of Family and Community Medicine at San Francisco General Hospital (SFGH) provides clinical consultation and education for health care providers; the Warmline is in operation on weekdays at 1-800-933-3413. Our National Clinicians' Post-Exposure Prophylaxis Hotline (pEPline) at 1-888-HIV-4911 provides 24-hour advice and support regarding occupational exposures to HIV and other blood-borne pathogens. The AIDS Education and Training Centers (AIDS ETCs) of the Health Resources and Services Administration (HRSA) at 1-301-443-6364 offers education, training, and consultation services to health care providers.
